William Plauche, MD
Ophthalmology · Sherman, TXNPI 1871535674
Payments from drug & device makers
Across 215 payments — averaging $91.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bausch & Lomb Americas Inc.$13K
- Glaukos Corporation$1K
- Ivantis, Inc$1K
- Alcon$633
- Bausch & Lomb, A Division Of Bausch Health US, LLC$629
- Biotissue Holdings Inc.$382
- plus $2K from 25 others
What the payments were for
- Consulting fees$11,92561%
- Speaking & faculty fees$1,0765%
- Food & beverage$6,54233%
- Education$210%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bausch & Lomb Americas Inc. | 34 | $13,357 |
| Glaukos Corporation | 19 | $1,244 |
| Ivantis, Inc | 3 | $1,067 |
| Alcon | 49 | $633 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 18 | $629 |
| Biotissue Holdings Inc. | 30 | $382 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $293 |
| Rxsight Inc | 6 | $252 |
| AbbVie(2 entities) | 8 | $217 |
| Sight Sciences, Inc. | 11 | $211 |
| Ocular Therapeutix, Inc. | 2 | $198 |
| Ellexiscience | 1 | $192 |
| Notal Vision, Inc. | 1 | $150 |
| Regeneron Healthcare Solutions, Inc. | 4 | $119 |
| Bausch Health US, LLC | 1 | $102 |
| Novartis | 3 | $85 |
| Beaver-visitec International, Inc. | 2 | $82 |
| Lensar, Inc. | 1 | $74 |
| Dompe US, Inc. | 3 | $53 |
| Harrow Eye, LLC | 1 | $38 |
| Amgen | 2 | $35 |
| Nova Eye, Inc. | 1 | $32 |
| Genentech USA, Inc. | 1 | $26 |
| Pacira Pharmaceuticals Incorporated | 1 | $26 |
| Carl Zeiss Meditec, Inc. | 1 | $20 |
| Tearlab Corp | 1 | $18 |
| NEW World Medical,inc. | 1 | $17 |
| Carl Zeiss Meditec USA, Inc. | 1 | $15 |
| Rayner Intraocular Lenses Limited | 1 | $14 |
| Aerie Pharmaceuticals, Inc. | 1 | $14 |
| Omeros Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- enVista MX60 IOL$7,144
- Hydrus$1,000
- IC-8 Apthera IOL$900
- ENVISTA ENVY IOL$259
- KXL System$217
- Photrexa$217
- iDoseTR$214
- Tecnis IOL$152
- RXSIGHT CONTACT LENS$146
- RXSIGHT INJECTOR CARTRIDGE$146
- RXSIGHT INJECTOR HANDPIECE$146
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$146
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$146
- ENVISTA$120
- STELLARIS$110
- iDose$106
- iStent inject Trabecular Micro-Bypass Stent System$104
- iStent inject W$103
- DEXTENZA$101
How this compares
$19,608 in reported general payments places this provider in the 85th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 52 | $24,063 |
| Prednisolone Acetate | 388 | $10,780 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 38 | $8,121 |
| RestasisCyclosporine | 13 | $7,671 |
| RocklatanNetarsudil Mesylat/Latanoprost | 14 | $6,545 |
| Lotemax SmLoteprednol Etabonate | 25 | $6,271 |
| ProlensaBromfenac Sodium | 13 | $4,829 |
| Travoprost | 42 | $4,725 |
| Brimonidine Tartrate | 230 | $4,387 |
| MoxifloxacinMoxifloxacin Hcl | 166 | $4,265 |
| CombiganBrimonidine Tartrate/Timolol | 19 | $4,183 |
| Fluorometholone | 45 | $3,164 |
| Loteprednol Etabonate | 21 | $2,368 |
| Cyclosporine | 11 | $1,936 |
| Latanoprost | 370 | $1,823 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan | $217 | $35,91784 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm, Prolensa, Loteprednol Etabonate | $629 | $13,46759 claims |
| AlconSimbrinza | $633 | $8,12138 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $14 | $6,54514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Sherman
- Charles WykoffBellaire$73.4M
- David BrownHouston$51.7M
- Sunil PatelAbilene$11.1M
- Chirag JhaveriAustin$9.4M
- Robert WongAustin$6.6M
- Fuad MakkoukAustin$6.6M
- Patrick WilliamsArlington$6.6M
- Ashkan AbbeyDallas$5.7M
- Karl CsakyDallas$4.9M
- Michael SingerSan Antonio$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.